NAPLES, Fla., April 12, 2021 /PRNewswire/ -- Enveric
Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a
patient-first biotechnology company developing novel cannabinoid
medicines to improve quality of life for cancer patients, today
announced that it has appointed Carter
Ward as Chief Financial Officer, effective May 15th, 2021. Mr. Ward is replacing
John Van Buiten, who is expected to
remain in a consulting role with the company, supporting Mr. Ward
both during the transition and moving forward.
"Mr. Ward will be joining our team with extensive public company
leadership experience in life sciences, SEC reporting and the
capital markets," said David
Johnson, Chairman and CEO of Enveric. "Having a hands-on
financial leader who has managed companies in various stages, from
startup to expansion and turnaround, I have no doubt that Mr. Ward
will help to continue driving the growth and success at Enveric.
Our team sincerely thanks Mr. Van
Buiten for his dedication to the Company, especially his
commitment in working tirelessly with management through our recent
go-public transaction. We are excited that he will remain with
Enveric as a consultant."
Prior to joining Enveric, Mr. Ward, who has over 30 years of
industry experience after starting his career at KPMG, most
recently served as CFO at Elite Pharmaceuticals, a specialty
pharmaceutical company that develops and manufactures oral,
controlled-release products using proprietary technology for
manufacturing generic pharmaceuticals. During his tenure there, Mr.
Ward successfully negotiated and executed capital raises, developed
strategic initiatives, created financial models and led financial
reporting efforts.
Before joining Elite, Mr. Ward also worked on the finance and
supply chain team at Actavis USA,
the U.S. subsidiary of European-based Actavis Group. At Actavis,
Mr. Ward spearheaded the successful reengineering of the company's
outbound supply chain, achieving a $3.5
million annual cost reduction and 75 percent improvement in
order-to-delivery time. Additionally, Mr. Ward worked at Centennial
Communications, and internationally at Ceejay Healthcare in
India and Petro Pharma in
Singapore.
"Since becoming a public company in late-December 2020, Enveric has already achieved
notable strategic milestones, working diligently to execute its
vision of bringing new-generation, naturally occurring and
synthetic compounds to cancer patients who need better, safer
supportive care treatments," added Mr. Ward. "In my new role as CFO
at Enveric, I look forward to working closely with the team to
continue pushing these goals forward and advance the Company's drug
pipeline, making more effective cancer care a reality for patients
suffering around the world."
Mr. Ward is a New York State
Certified Public Accountant (CPA) and Certified Supply Chain
Professional (CSCP). He obtained his Bachelor of Science degree in
accounting from Long Island University in
Brooklyn, N.Y, graduating summa cum laude.
About Enveric Biosciences
Enveric Biosciences is a
patient-first biotechnology company developing rigorously tested,
novel cannabinoid medicines to improve quality of life for cancer
patients. Initial indications include radiodermatitis, a common and
often severe side effect of radiation therapy, and
chemotherapy-induced neuropathy. For more information, please visit
https://www.enveric.com/.
Forward-Looking Statements
This press release contains
forward-looking statements and forward-looking information within
the meaning of applicable securities laws. These statements relate
to future events or future performance. All statements other than
statements of historical fact may be forward-looking statements or
information. Generally, forward-looking statements and information
may be identified by the use of forward-looking terminology such as
"plans", " expects" or "does not expect", "proposed", "is
expected", "budgets", "scheduled", "estimates", "forecasts",
"intends", "anticipates" or "does not anticipate", or "believes",
or variations of such words and phrases, or by the use of words or
phrases which state that certain actions, events or results may,
could, would, or might occur or be achieved. Forward-looking
statements consist of statements that are not purely historical,
including any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking
statements are based on the beliefs of management as well as
assumptions made by and information currently available to
management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including, but not limited to, the impact of the
novel coronavirus (COVID-19) on Enveric's ongoing and planned
clinical trials; the geographic, social and economic impact of
COVID-19 on Enveric's ability to conduct its business and raise
capital in the future when needed; delays in planned clinical
trials; the ability to establish that potential products are
efficacious or safe in preclinical or clinical trials; the ability
to establish or maintain collaborations on the development of
therapeutic candidates; the ability to obtain appropriate or
necessary governmental approvals to market potential products; the
ability to obtain future funding for developmental products and
working capital and to obtain such funding on commercially
reasonable terms; Enveric's ability to manufacture product
candidates on a commercial scale or in collaborations with third
parties; changes in the size and nature of competitors; the ability
to retain key executives and scientists; and the ability to secure
and enforce legal rights related to Enveric's products, including
patent protection. A discussion of these and other factors,
including risks and uncertainties with respect to Enveric, is set
forth in Enveric's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any
intention or obligation to revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Investor Contacts
Valter
Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
valter@kcsa.com / asoss@kcsa.com
Media Contacts
Caitlin
Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
ckasunich@kcsa.com / rcona@kcsa.com
View original
content:http://www.prnewswire.com/news-releases/enveric-biosciences-appoints-carter-ward-as-chief-financial-officer-301266318.html
SOURCE Enveric Biosciences